{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:06:27Z","timestamp":1791860787037,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T00:00:00Z","timestamp":1625356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T00:00:00Z","timestamp":1625356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201603PJT 364544"],"award-info":[{"award-number":["201603PJT 364544"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30AG10161"],"award-info":[{"award-number":["P30AG10161"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG15819"],"award-info":[{"award-number":["R01AG15819"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Brain inflammation has been increasingly associated with early amyloid accumulation in Alzheimer\u2019s disease models; however, evidence of its occurrence in humans remains scarce. To elucidate whether amyloid deposition is associated with neuroinflammation and cognitive deficits, we studied brain inflammatory cytokine expression and cognitive decline in non-demented elderly individuals with and without cerebral amyloid-beta deposition.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Global cognition, episodic, working, and semantic memory, perceptual speed, visuospatial ability, and longitudinal decline (5.7 \u00b1 3.6 years) in each cognitive domain were compared between elderly individuals (66\u201379 years) with and without cerebral amyloid-beta deposition. The expression of 20 inflammatory cytokines was analyzed in frozen temporal, parietal, and frontal cortices and compared between older individuals with and without amyloid-beta deposition in each brain region. Correlation analyses were performed to analyze associations between amyloid-beta load, cytokine expression, and cognitive decline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Individuals with cortical amyloid-beta deposition displayed deficits and a faster rate of cognitive decline in perceptual speed as compared with those individuals without amyloid-beta. This decline was positively associated with cortical amyloid-beta levels. Elderly individuals with amyloid-beta deposition had higher levels of IL-1\u03b2, IL-6, and eotaxin-3 in the temporal cortex accompanied by an increase in MCP-1 and IL-1\u03b2 in the parietal cortex and a trend towards higher levels of IL-1\u03b2 and MCP-1 in the frontal cortex as compared with age-matched amyloid-free individuals. Brain IL-1\u03b2 levels displayed a positive association with cortical amyloid burden in each brain region. Finally, differential cytokine expression in each cortical region was associated with cognitive decline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Elderly individuals with amyloid-beta neuropathology but no symptomatic manifestation of dementia, exhibit cognitive decline and increased brain cytokine expression. Such observations suggest that increased cytokine expression might be an early event in the Alzheimer\u2019s continuum.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12974-021-02169-0","type":"journal-article","created":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T07:02:27Z","timestamp":1625382147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cognitive and brain cytokine profile of non-demented individuals with cerebral amyloid-beta deposition"],"prefix":"10.1186","volume":"18","author":[{"given":"Lisi","family":"Flores-Aguilar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Florencia","family":"Iulita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Orciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Tanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-2745","authenticated-orcid":false,"given":"A. Claudio","family":"Cuello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,4]]},"reference":[{"issue":"4","key":"2169_CR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00401-013-1177-7","volume":"126","author":"PL McGeer","year":"2013","unstructured":"McGeer PL, McGeer EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 2013;126(4):479\u201397. https:\/\/doi.org\/10.1007\/s00401-013-1177-7.","journal-title":"Acta Neuropathol"},{"issue":"19","key":"2169_CR2","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1212\/01.wnl.0000311269.57716.63","volume":"70","author":"SC Vlad","year":"2008","unstructured":"Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 2008;70(19):1672\u20137. https:\/\/doi.org\/10.1212\/01.wnl.0000311269.57716.63.","journal-title":"Neurology."},{"issue":"11","key":"2169_CR3","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jalz.2018.01.008","volume":"14","author":"J Rogers","year":"2018","unstructured":"Rogers J. Principles for central nervous system inflammation research: a call for a consortium approach. Alzheimers Dement. 2018;14(11):1553\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2018.01.008.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"2169_CR4","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.tips.2017.07.005","volume":"38","author":"AC Cuello","year":"2017","unstructured":"Cuello AC. Early and late CNS inflammation in Alzheimer's disease: two extremes of a continuum? Trends Pharmacol Sci. 2017;38(11):956\u201366. https:\/\/doi.org\/10.1016\/j.tips.2017.07.005.","journal-title":"Trends Pharmacol Sci"},{"issue":"10","key":"2169_CR5","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1016\/j.neurobiolaging.2014.03.026","volume":"35","author":"CE Hanzel","year":"2014","unstructured":"Hanzel CE, Pichet-Binette A, Pimentel LS, Iulita MF, Allard S, Ducatenzeiler A, et al. Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease. Neurobiol Aging. 2014;35(10):2249\u201362. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2014.03.026.","journal-title":"Neurobiol Aging"},{"issue":"7","key":"2169_CR6","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.neurobiolaging.2011.01.007","volume":"33","author":"MT Ferretti","year":"2012","unstructured":"Ferretti MT, Bruno MA, Ducatenzeiler A, Klein WL, Cuello AC. Intracellular Abeta-oligomers and early inflammation in a model of Alzheimer's disease. Neurobiol Aging. 2012;33(7):1329\u201342. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.01.007.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"2169_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.nbd.2009.01.006","volume":"34","author":"FE McAlpine","year":"2009","unstructured":"McAlpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis. 2009;34(1):163\u201377. https:\/\/doi.org\/10.1016\/j.nbd.2009.01.006.","journal-title":"Neurobiol Dis"},{"key":"2169_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.neurobiolaging.2016.07.009","volume":"47","author":"C Cavanagh","year":"2016","unstructured":"Cavanagh C, Tse YC, Nguyen HB, Krantic S, Breitner JC, Quirion R, et al. Inhibiting tumor necrosis factor-alpha before amyloidosis prevents synaptic deficits in an Alzheimer's disease model. Neurobiol Aging. 2016;47:41\u20139. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.07.009.","journal-title":"Neurobiol Aging"},{"issue":"12","key":"2169_CR9","doi-asserted-by":"publisher","first-page":"6844","DOI":"10.1073\/pnas.1914593117","volume":"117","author":"LA Welikovitch","year":"2020","unstructured":"Welikovitch LA, Do Carmo S, Magloczky Z, Malcolm JC, Loke J, Klein WL, et al. Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain. Proc Natl Acad Sci U S A. 2020;117(12):6844\u201354. https:\/\/doi.org\/10.1073\/pnas.1914593117.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2169_CR10","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","volume":"66","author":"DA Bennett","year":"2006","unstructured":"Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837\u201344. https:\/\/doi.org\/10.1212\/01.wnl.0000219668.47116.e6.","journal-title":"Neurology."},{"issue":"8","key":"2169_CR11","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/archneurol.2010.179","volume":"67","author":"G De Meyer","year":"2010","unstructured":"De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol. 2010;67(8):949\u201356. https:\/\/doi.org\/10.1001\/archneurol.2010.179.","journal-title":"Arch Neurol"},{"issue":"8-9","key":"2169_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/emmm.200900048","volume":"1","author":"AM Fagan","year":"2009","unstructured":"Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med. 2009;1(8-9):371\u201380. https:\/\/doi.org\/10.1002\/emmm.200900048.","journal-title":"EMBO Mol Med"},{"issue":"3","key":"2169_CR13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1212\/WNL.46.3.707","volume":"46","author":"JC Morris","year":"1996","unstructured":"Morris JC, Storandt M, McKeel DW Jr, Rubin EH, Price JL, Grant EA, et al. Cerebral amyloid deposition and diffuse plaques in \"normal\" aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology. 1996;46(3):707\u201319. https:\/\/doi.org\/10.1212\/WNL.46.3.707.","journal-title":"Neurology."},{"issue":"24","key":"2169_CR14","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1212\/01.wnl.0000271090.28148.24","volume":"69","author":"JA Schneider","year":"2007","unstructured":"Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197\u2013204. https:\/\/doi.org\/10.1212\/01.wnl.0000271090.28148.24.","journal-title":"Neurology."},{"issue":"1","key":"2169_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1162\/jocn_a_00300","volume":"25","author":"EJ Rogalski","year":"2013","unstructured":"Rogalski EJ, Gefen T, Shi J, Samimi M, Bigio E, Weintraub S, et al. Youthful memory capacity in old brains: anatomic and genetic clues from the northwestern SuperAging project. J Cogn Neurosci. 2013;25(1):29\u201336. https:\/\/doi.org\/10.1162\/jocn_a_00300.","journal-title":"J Cogn Neurosci"},{"issue":"5","key":"2169_CR16","doi-asserted-by":"publisher","first-page":"1017 e1","DOI":"10.1016\/j.neurobiolaging.2011.09.033","volume":"33","author":"PL De Jager","year":"2012","unstructured":"De Jager PL, Shulman JM, Chibnik LB, Keenan BT, Raj T, Wilson RS, et al. A genome-wide scan for common variants affecting the rate of age-related cognitive decline. Neurobiol Aging. 2012;33(5):1017 e1\u201315.","journal-title":"Neurobiol Aging"},{"issue":"4","key":"2169_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/ana.23654","volume":"72","author":"DA Bennett","year":"2012","unstructured":"Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA. Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol. 2012;72(4):599\u2013609. https:\/\/doi.org\/10.1002\/ana.23654.","journal-title":"Ann Neurol"},{"issue":"1","key":"2169_CR18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.dadm.2016.09.002","volume":"6","author":"JE Baker","year":"2017","unstructured":"Baker JE, Lim YY, Pietrzak RH, Hassenstab J, Snyder PJ, Masters CL, et al. Cognitive impairment and decline in cognitively normal older adults with high amyloid-beta: a meta-analysis. Alzheimers Dement (Amst). 2017;6(1):108\u201321. https:\/\/doi.org\/10.1016\/j.dadm.2016.09.002.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"5","key":"2169_CR19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/0197-4580(96)00104-2","volume":"17","author":"JG Sheng","year":"1996","unstructured":"Sheng JG, Ito K, Skinner RD, Mrak RE, Rovnaghi CR, Van Eldik LJ, et al. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging. 1996;17(5):761\u20136. https:\/\/doi.org\/10.1016\/0197-4580(96)00104-2.","journal-title":"Neurobiol Aging"},{"issue":"10","key":"2169_CR20","doi-asserted-by":"publisher","first-page":"6421","DOI":"10.1074\/jbc.274.10.6421","volume":"274","author":"JT Rogers","year":"1999","unstructured":"Rogers JT, Leiter LM, McPhee J, Cahill CM, Zhan SS, Potter H, et al. Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences. J Biol Chem. 1999;274(10):6421\u201331. https:\/\/doi.org\/10.1074\/jbc.274.10.6421.","journal-title":"J Biol Chem"},{"issue":"1","key":"2169_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1742-2094-3-5","volume":"3","author":"WS Griffin","year":"2006","unstructured":"Griffin WS, Liu L, Li Y, Mrak RE, Barger SW. Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflammation. 2006;3(1):5. https:\/\/doi.org\/10.1186\/1742-2094-3-5.","journal-title":"J Neuroinflammation"},{"issue":"6","key":"2169_CR22","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/00005072-198911000-00009","volume":"48","author":"JM Rozemuller","year":"1989","unstructured":"Rozemuller JM, Eikelenboom P, Stam FC, Beyreuther K, Masters CL. A4 protein in Alzheimer's disease: primary and secondary cellular events in extracellular amyloid deposition. J Neuropathol Exp Neurol. 1989;48(6):674\u201391. https:\/\/doi.org\/10.1097\/00005072-198911000-00009.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"7434","key":"2169_CR23","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature11729","volume":"493","author":"MT Heneka","year":"2013","unstructured":"Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP\/PS1 mice. Nature. 2013;493(7434):674\u20138. https:\/\/doi.org\/10.1038\/nature11729.","journal-title":"Nature."},{"issue":"19","key":"2169_CR24","doi-asserted-by":"publisher","first-page":"7611","DOI":"10.1073\/pnas.86.19.7611","volume":"86","author":"WS Griffin","year":"1989","unstructured":"Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A. 1989;86(19):7611\u20135. https:\/\/doi.org\/10.1073\/pnas.86.19.7611.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2169_CR25","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.1093\/brain\/awaa326","volume":"143","author":"L Flores-Aguilar","year":"2020","unstructured":"Flores-Aguilar L, Iulita MF, Kovecses O, Torres MD, Levi SM, Zhang Y, et al. Evolution of neuroinflammation across the lifespan of individuals with Down syndrome. Brain. 2020;143(12):3653.","journal-title":"Brain"},{"issue":"2","key":"2169_CR26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/jnr.20266","volume":"78","author":"A Basu","year":"2004","unstructured":"Basu A, Krady JK, Levison SW. Interleukin-1: a master regulator of neuroinflammation. J Neurosci Res. 2004;78(2):151\u20136. https:\/\/doi.org\/10.1002\/jnr.20266.","journal-title":"J Neurosci Res"},{"issue":"5","key":"2169_CR27","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/0197-4580(96)00107-8","volume":"17","author":"M Hull","year":"1996","unstructured":"Hull M, Fiebich BL, Lieb K, Strauss S, Berger SS, Volk B, et al. Interleukin-6-associated inflammatory processes in Alzheimer's disease: new therapeutic options. Neurobiol Aging. 1996;17(5):795\u2013800. https:\/\/doi.org\/10.1016\/0197-4580(96)00107-8.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"2169_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0169-328X(97)00356-2","volume":"55","author":"GE Ringheim","year":"1998","unstructured":"Ringheim GE, Szczepanik AM, Petko W, Burgher KL, Zhu SZ, Chao CC. Enhancement of beta-amyloid precursor protein transcription and expression by the soluble interleukin-6 receptor\/interleukin-6 complex. Brain Res Mol Brain Res. 1998;55(1):35\u201344. https:\/\/doi.org\/10.1016\/S0169-328X(97)00356-2.","journal-title":"Brain Res Mol Brain Res"},{"issue":"1","key":"2169_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.yexcr.2004.01.002","volume":"295","author":"RA Quintanilla","year":"2004","unstructured":"Quintanilla RA, Orellana DI, Gonzalez-Billault C, Maccioni RB. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5\/p35 pathway. Exp Cell Res. 2004;295(1):245\u201357. https:\/\/doi.org\/10.1016\/j.yexcr.2004.01.002.","journal-title":"Exp Cell Res"},{"issue":"2","key":"2169_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/sj.mp.4000225","volume":"2","author":"IL Campbell","year":"1997","unstructured":"Campbell IL, Stalder AK, Chiang CS, Bellinger R, Heyser CJ, Steffensen S, et al. Transgenic models to assess the pathogenic actions of cytokines in the central nervous system. Mol Psychiatry. 1997;2(2):125\u20139. https:\/\/doi.org\/10.1038\/sj.mp.4000225.","journal-title":"Mol Psychiatry"},{"issue":"11","key":"2169_CR31","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1001\/archneur.58.11.1790","volume":"58","author":"PL McGeer","year":"2001","unstructured":"McGeer PL, McGeer EG. Polymorphisms in inflammatory genes and the risk of Alzheimer disease. Arch Neurol. 2001;58(11):1790\u20132. https:\/\/doi.org\/10.1001\/archneur.58.11.1790.","journal-title":"Arch Neurol"},{"issue":"8","key":"2169_CR32","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.neurobiolaging.2003.10.016","volume":"25","author":"R Li","year":"2004","unstructured":"Li R, Strohmeyer R, Liang Z, Lue LF, Rogers J. CCAAT\/enhancer binding protein delta (C\/EBPdelta) expression and elevation in Alzheimer's disease. Neurobiol Aging. 2004;25(8):991\u20139. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2003.10.016.","journal-title":"Neurobiol Aging"},{"issue":"4","key":"2169_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018850","volume":"6","author":"R Craig-Schapiro","year":"2011","unstructured":"Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, et al. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One. 2011;6(4):e18850. https:\/\/doi.org\/10.1371\/journal.pone.0018850.","journal-title":"PLoS One"},{"issue":"1","key":"2169_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030525","volume":"7","author":"K Westin","year":"2012","unstructured":"Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PLoS One. 2012;7(1):e30525. https:\/\/doi.org\/10.1371\/journal.pone.0030525.","journal-title":"PLoS One"},{"issue":"6","key":"2169_CR35","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00401-010-0667-0","volume":"119","author":"WT Hu","year":"2010","unstructured":"Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, et al. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol. 2010;119(6):669\u201378. https:\/\/doi.org\/10.1007\/s00401-010-0667-0.","journal-title":"Acta Neuropathol"},{"issue":"16","key":"2169_CR36","doi-asserted-by":"publisher","first-page":"6208","DOI":"10.1523\/JNEUROSCI.0299-11.2011","volume":"31","author":"G Naert","year":"2011","unstructured":"Naert G, Rivest S. CC chemokine receptor 2 deficiency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2011;31(16):6208\u201320. https:\/\/doi.org\/10.1523\/JNEUROSCI.0299-11.2011.","journal-title":"J Neurosci"},{"issue":"4","key":"2169_CR37","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/nm1555","volume":"13","author":"J El Khoury","year":"2007","unstructured":"El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007;13(4):432\u20138. https:\/\/doi.org\/10.1038\/nm1555.","journal-title":"Nat Med"},{"issue":"4","key":"2169_CR38","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1001\/archneur.63.4.538","volume":"63","author":"D Galimberti","year":"2006","unstructured":"Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E, et al. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol. 2006;63(4):538\u201343. https:\/\/doi.org\/10.1001\/archneur.63.4.538.","journal-title":"Arch Neurol"},{"issue":"3","key":"2169_CR39","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1750-3639.2008.00188.x","volume":"19","author":"A Sokolova","year":"2009","unstructured":"Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE. Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol. 2009;19(3):392\u20138. https:\/\/doi.org\/10.1111\/j.1750-3639.2008.00188.x.","journal-title":"Brain Pathol"},{"issue":"9","key":"2169_CR40","doi-asserted-by":"publisher","first-page":"e867","DOI":"10.1212\/WNL.0000000000006082","volume":"91","author":"S Janelidze","year":"2018","unstructured":"Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. 2018;91(9):e867\u2013e77. https:\/\/doi.org\/10.1212\/WNL.0000000000006082.","journal-title":"Neurology."},{"issue":"Pt 3","key":"2169_CR41","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/brain\/awv404","volume":"139","author":"E Rodriguez-Vieitez","year":"2016","unstructured":"Rodriguez-Vieitez E, Saint-Aubert L, Carter SF, Almkvist O, Farid K, Scholl M, et al. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease. Brain. 2016;139(Pt 3):922\u201336. https:\/\/doi.org\/10.1093\/brain\/awv404.","journal-title":"Brain."},{"key":"2169_CR42","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.nbd.2018.10.009","volume":"121","author":"I Barroeta-Espar","year":"2019","unstructured":"Barroeta-Espar I, Weinstock LD, Perez-Nievas BG, Meltzer AC, Siao Tick Chong M, Amaral AC, et al. Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. Neurobiol Dis. 2019;121:327\u201337. https:\/\/doi.org\/10.1016\/j.nbd.2018.10.009.","journal-title":"Neurobiol Dis"},{"issue":"Pt 8","key":"2169_CR43","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1093\/brain\/awt171","volume":"136","author":"BG Perez-Nievas","year":"2013","unstructured":"Perez-Nievas BG, Stein TD, Tai HC, Dols-Icardo O, Scotton TC, Barroeta-Espar I, et al. Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain. 2013;136(Pt 8):2510\u201326. https:\/\/doi.org\/10.1093\/brain\/awt171.","journal-title":"Brain."},{"key":"2169_CR44","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fnagi.2019.00094","volume":"11","author":"T Gefen","year":"2019","unstructured":"Gefen T, Kim G, Bolbolan K, Geoly A, Ohm D, Oboudiyat C, et al. Activated microglia in cortical white matter across cognitive aging trajectories. Front Aging Neurosci. 2019;11:94. https:\/\/doi.org\/10.3389\/fnagi.2019.00094.","journal-title":"Front Aging Neurosci"},{"key":"2169_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2016.02.030","volume":"42","author":"SW Scheff","year":"2016","unstructured":"Scheff SW, Ansari MA, Mufson EJ. Oxidative stress and hippocampal synaptic protein levels in elderly cognitively intact individuals with Alzheimer's disease pathology. Neurobiol Aging. 2016;42:1\u201312. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.02.030.","journal-title":"Neurobiol Aging"},{"key":"2169_CR46","doi-asserted-by":"publisher","unstructured":"Pentz R, Iulita MF, Ducatenzeiler A, AC BDAC. The human brain NGF metabolic pathway is impaired in the pre-clinical and clinical continuum of Alzheimers disease. Mol Psychiatry. 2020. https:\/\/doi.org\/10.1038\/s41380-020-0797-2.","DOI":"10.1038\/s41380-020-0797-2"},{"issue":"9","key":"2169_CR47","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/nn.3786","volume":"17","author":"PL De Jager","year":"2014","unstructured":"De Jager PL, Srivastava G, Lunnon K, Burgess J, Schalkwyk LC, Yu L, et al. Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat Neurosci. 2014;17(9):1156\u201363. https:\/\/doi.org\/10.1038\/nn.3786.","journal-title":"Nat Neurosci"},{"issue":"2","key":"2169_CR48","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s12035-014-8657-1","volume":"50","author":"F Brosseron","year":"2014","unstructured":"Brosseron F, Krauthausen M, Kummer M, Heneka MT. Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Mol Neurobiol. 2014;50(2):534\u201344. https:\/\/doi.org\/10.1007\/s12035-014-8657-1.","journal-title":"Mol Neurobiol"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-021-02169-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-021-02169-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-021-02169-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T07:02:38Z","timestamp":1625382158000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-021-02169-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,4]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2169"],"URL":"https:\/\/doi.org\/10.1186\/s12974-021-02169-0","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,4]]},"assertion":[{"value":"4 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project has been approved by the McGill University Research Ethics Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}